Potenciál využitia galectinu-3 a PIVKA II v hepatológii / The potential use of galectin-3 and PIVKA II in hepatology

SÚHRN Galectin-3 (GAL3) je biomarker fibrózy s prednostným využitím v kardiológii, pribúdajú práce popisujúce jeho využitie v nefrológii, hepatológii a pneumológii. PIVKA II je kandidátnym biomarkerom hepatocelulárneho karcinómu a iných chorôb pečene. Literárne dáta o využití oboch biomarkerov u pacientov po transplantácii pečene sú zatiaľ obmedzené. ABSTRACT Galectin-3 (GAL3) is an emerging biomarker of fibrosis, used mainly in the field of cardiology; however, increasing evidence is available for the use of GAL3 in nephrology, hepatology, and pneumology. PIVKA II is a candidate biomarker of hepatocellular cancer and other diseases of the liver. Data on the use of both biomarkers in patients after liver transplantation (LTx) are rather scarce.

Related Organizations

Charles University
Czech Republic

Keywords

PIVKA II, galectin-3, transplantácia pečene / liver transplantation

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average